Loading…
for educational and safety purposes
Aripiprazole and Olanzapine both come up in the same conversations; they overlap on dopamine D2 receptors and mood/psychosis. Aripiprazole: Aripiprazole is a second-generation (atypical) antipsychotic used in schizophrenia, bipolar disorder and as an adjunct in major depression. Olanzapine: Olanzapine is an atypical, or second-generation, antipsychotic used to treat schizophrenia and bipolar disorder.
Aripiprazole is a second-generation (atypical) antipsychotic used in schizophrenia, bipolar disorder and as an adjunct in major depression. Rather than fully blocking dopamine D2 receptors like older agents, it acts as a high-affinity partial agonist, combined with partial agonism at serotonin 5-HT1A and antagonism at 5-HT2A receptors, so that it behaves as a dopamine system stabilizer that dampens signaling where dopamine is excessive and supports it where dopamine is deficient. This mechanism gives it antipsychotic efficacy comparable to other agents with relatively little sedation, weight gain, movement disorder or prolactin elevation, and it is also formulated as a long-acting monthly injection to support adherence. The same partial-agonist pharmacology, however, can occasionally provoke impulse-control problems such as pathological gambling, an effect it shares with dopamine agonists.
Olanzapine is an atypical, or second-generation, antipsychotic used to treat schizophrenia and bipolar disorder. Chemically a thienobenzodiazepine, it was discovered in a search for compounds resembling clozapine but without that drug's blood-monitoring requirement, and it works by blocking a broad range of dopamine and serotonin receptors. Beyond psychiatry it is a highly effective antiemetic and appetite stimulant even at very low doses, which is used in cancer care, though it is among the antipsychotics most likely to cause weight gain and metabolic problems, prompting the development of an olanzapine-samidorphan combination to blunt that effect.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
modulates
antagonist
antagonist
antagonist
modulates
activates
antagonist
antagonist
antagonist
antagonist
antagonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.